Vedolizumab - Takeda Oncology

Drug Profile

Vedolizumab - Takeda Oncology

Alternative Names: Entyvio; Kynteles; LDP-02; LPD-02; MLN-0002; MLN-002; MLN02

Latest Information Update: 26 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Medical College of Wisconsin; Millennium; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Ulcerative colitis
  • Phase II Coeliac disease; Graft-versus-host disease
  • Phase I Malignant melanoma

Most Recent Events

  • 03 Sep 2018 Millennium Pharmaceuticals plans a phase III trial for Graft Versus-Host Disease in November 2018, (NCT03657160)
  • 21 Aug 2018 Takeda completes the VISIBLE 1 phase III trial in Ulcerative colitis (In adults, In the elderly) in Argentina, Australia, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Sweden, Turkey, Ukraine, the United Kingdom, and the USA (SC) (NCT02611830)
  • 26 Jul 2018 Takeda completes a phase I pharmacokinetic trial in healthy volunteers in China (IV) (NCT03329209)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top